

External Quality Assessment Program for

HPV-associated head and neck cancer

Labquality EQAS by Aurevia is introducing a new EQA scheme for Human papillomavirus (HPV) - associated head and neck cancer by arranging a pilot study free of charge for a limited number of participants. The scheme is intended for both clinical pathology and virology laboratories.

According to the need of the participant, the test round includes either one or two sample types. The paraffin sections are intended for p16 immunohistochemical staining (IHC) and the paraffin scrolls for HPV nucleic acid detection. Samples should be analysed as regular patient samples according to the process of the laboratory. Results are reported in the electronic platform LabScala. They are processed by the EQA Coordinator and evaluated according to the expected results.

6800 HPV-associated head and neck cancer

- Samples: 2 cell derived samples each including one paraffin section on slide for IHC p16 and/or paraffin scrolls in a vial for NAT
- Distribution: March 2025
- Registration: Please register by [this link](#) or by scanning this QR code no later than 24 February 2025



For more information

Aurevia's customer service info@aurevia.com or

Pia Eloranta
EQA Coordinator
pia.eloranta@aurevia.com
+358 50 3627 942

Heidi Berghäll
EQA Solutions manager, R&D
heidi.berghall@aurevia.com
+358 50 356 0503